3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cyclophosphamide
9
Rituximab
6
Tacrolimus
5
Busulfan
5
fludarabine phosphate
4
blinatumomab
4
Vincristine
4
Prednisone
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Etoposide
4
Doxorubicin
4
fludarabine
3
Whole-Body Irradiation
3
Valganciclovir
3
Everolimus
3
venetoclax
2
dacetuzumab
2
cobomarsen
2
Thiotepa
2
Sirolimus
2
Patient Reported Outcome Measures
2
Methotrexate
2
Mesna
2
Melphalan
2
Filgrastim
2
Epoetin Alfa
2
Antilymphocyte Serum
2
sargramostim
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoproliferative Disorders
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled